Quest PharmaTech Inc. (QPTFF)
| Market Cap | 4.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -177.05K |
| Shares Out | n/a |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Average Volume | 64,269 |
| Open | 0.0133 |
| Previous Close | 0.0150 |
| Day's Range | 0.0133 - 0.0133 |
| 52-Week Range | 0.0133 - 0.0400 |
| Beta | -0.13 |
| RSI | 21.67 |
| Earnings Date | Sep 22, 2025 |
About Quest PharmaTech
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada. [Read more]
News
Quest PharmaTech Announces Opposition to OQPBIOM’s Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of...
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality o...